Zevra Therapeutics (ZVRA) Income towards Parent Company (2014 - 2026)

Zevra Therapeutics (ZVRA) has 13 years of Income towards Parent Company data on file, last reported at $37.9 million in Q1 2026.

• Quarterly Income towards Parent Company rose 1322.65% year-over-year to $37.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $124.2 million (up 235.04% YoY) and the FY2025 annual result came in at $83.2 million, up 178.88% from the prior year.
• Income towards Parent Company rose to $37.9 million in Q1 2026, from $12.2 million in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of $74.7 million in Q2 2025 to a low of -$35.7 million in Q4 2024.
• A 5-year average of -$3.0 million and a median of -$5.7 million in 2022 frame the typical range for Income towards Parent Company.
• Annual changes were most pronounced in 2024 — Income towards Parent Company slumped 674.39% — and 2026, when it jumped 1322.65%.
• Tracing ZVRA's Income towards Parent Company over 5 years: stood at -$3.0 million in 2022, then plunged by 569.31% to -$19.9 million in 2023, then slumped by 79.67% to -$35.7 million in 2024, then soared by 134.04% to $12.2 million in 2025, then jumped by 211.47% to $37.9 million in 2026.
• The last three Income towards Parent Company figures came in at $37.9 million (Q1 2026), $12.2 million (Q4 2025), and -$544000.0 (Q3 2025), per Business Quant data.